ACAD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ACADIA Pharmaceuticals Inc (ACAD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong analyst ratings, undervaluation at current levels, and promising pipeline, particularly remlifanserin, make it a compelling opportunity. Despite minor short-term price declines, the long-term growth potential outweighs the risks.
The technical indicators suggest a bullish trend. The MACD is positive and expanding, the RSI is neutral but leaning towards bullish, and moving averages are aligned in a bullish pattern (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 23.468, with resistance at 24.874 and 25.742, indicating room for upward movement.
Strong analyst ratings with multiple firms upgrading the stock and setting price targets between $31 and $
Promising pipeline with remlifanserin showing potential as a potent and safer second-generation treatment for Alzheimer's disease psychosis.
Q4 2025 earnings report highlights annual revenues exceeding $1 billion for the first time, showcasing growth.
Recent price decline (-4.25% in pre-market and -1.32% in regular market).
Negative CHMP trend vote on Daybue, though there is still a possibility of reversal.
In Q4 2025, revenue increased by 9.39% YoY to $283.99 million, and EPS rose by 167.44% YoY to 2.3. However, net income dropped to 0 (-100% YoY), and gross margin slightly declined to 90.77% (-0.91% YoY).
Analysts are overwhelmingly positive on ACAD, with multiple firms rating it as Outperform or Buy. Price targets range from $23 to $40, with the consensus highlighting the undervaluation of the stock and the potential of its pipeline, particularly remlifanserin.
